Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14

作者：

Chanthavanich, Pornthep ^{[1
]}

Limkittikul, Kriengsak ^{[1
]}

Sirivichayakul, Chukiat ^{[1
]}

Chokejindachai, Watcharee ^{[1
]}

Hattasingh, Weerawan ^{[1
]}

Pengsaa, Krisana ^{[1
]}

Surangsrirat, Surachai ^{[2
]}

Srisuwannaporn, Termsang ^{[2
]}

Kaewma, Benjawan ^{[2
]}

Yoksan, Sutee ^{[3
]}

Jun, Gao ^{[4
]}

Zhumu, Bai ^{[4
]}

机构：

[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand

[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand

[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand

[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期

关键词：

children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;

D O I：

10.1080/21645515.2017.1414763

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.

引用

页码：900 / 905

页数：6

共 50 条

[41] IMMUNOGENICITY AND STABILITY OF NATIONAL CULTURED INACTIVATED JAPANESE ENCEPHALITIS VACCINE
KHANINA, MK
BOCHKOVA, NG
GRACHEV, VP
ELBERT, LB
VOROBYEVA, MS
BORSUK, EA
POGODINA, VV
VOPROSY VIRUSOLOGII, 1990, 35 (06) : 478 - 480
[42] Persistence of antibodies in children after pre-exposure primary and booster immunizations with purified Vero cell rabies vaccine, chromatographically purified Vero cell rabies vaccine and human diploid cell vaccine
Sabchareon, A
RABIES CONTROL IN ASIA, 2001, : 29 - 41
[43] Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region
Dubischar, Katrin L.
Kadlecek, Vera
Sablan, Benjamin
Borja-Tabora, Charissa Fay
Gatchalian, Salvacion
Eder-Lingelbach, Susanne
Kiermayr, Sigrid
Spruth, Martin
Westritschnig, Kerstin
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (09) : 898 - 904
[44] Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients
Assawawiroonhakarn, Surapat
Apiwattanakul, Nopporn
Pakakasama, Samart
Hongeng, Suradej
Anurathapan, Usanarat
Yoksan, Sutee
Klinmalai, Chompunuch
Sae-Chew, Pattarana
Techasaensiri, Chonnamet
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (03) : 264 - 268
[45] JEVAC inactivated Japanese encephalitis vaccine (vero cell)Hypersensitivity reactions: 12 case reports
Reactions Weekly, 2015, 1539 (1) : 183 - 183
[46] JEVAC-inactivated-japanese-encephalitis-vaccine-(vero-cell)Agranulocytosis: case report
Reactions Weekly, 2022, 1888 (1) : 215 - 215
[47] Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine
Pierson, Benjamin C.
Cardile, Anthony P.
Okwesili, Arthur C.
Downs, Isaac L.
Reisler, Ronald B.
Boudreau, Ellen F.
Kortepeter, Mark G.
Koca, Craig D.
Ranadive, Manmohan, V
Petitt, Patricia L.
Kanesa-thasan, Niranjan
Rivard, Robert G.
Liggett, Dani L.
Haller, Jeannine M.
Norris, Sarah L.
Purcell, Bret K.
Pittman, Phillip R.
Saunders, David L.
Jahromi, Maryam Keshtkar
VACCINE, 2021, 39 (20) : 2780 - 2790
[48] Japanese encephalitis vaccine (inactivated, BIKEN) in US soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens
Defraites, RF
Gambel, JM
Hoke, CH
Sanchez, JL
Withers, BG
Karabatsos, N
Shope, RE
Tirrell, S
Yoshida, I
Takagi, M
Meschievitz, CK
Tsai, TF
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 61 (02): : 288 - 293
[49] FIRST CLINICAL TRIAL OF A VERO CELL DERIVED, INACTIVATED JAPANESE ENCEPHALITIS (JE) VACCINE IC51 IN PEDIATRIC POPULATION
Schuller, Elisabeth
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 246 - 246
[50] Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study
Jelinek, Tomas
Cromer, Michael A.
Cramer, Jakob P.
Mills, Deborah J.
Lessans, Kenneth
Gherardin, Anthony W.
Barnett, Elizabeth D.
Hagmann, Stefan H. F.
Askling, Helena H.
Kiermayr, Sigrid
Kadlecek, Vera
Eder-Lingelbach, Susanne
Taucher, Christian
Dubischar, Katrin L.
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2018, 22 : 18 - 24

← 1 2 3 4 5 →